Cell line development, protein expression, purification and analysis

Jianli (Charlie) Gong, Ph.D.

**** ***** ******, ********, *******, 917-***-****

acz252@r.postjobfree.com, acz252@r.postjobfree.com, linkedin.com/in/jianligong

SUMMARY OF QUALIFICATIONS

Highly motivated biomedical scientist with 10+ years of research and industrial experience in cancer biology and cardiology and proven track of record in operating high efficient research laboratories

Hands on skills in molecular biology, cell biology, biochemistry including vector construction, cell culture, cell line development, protein expression, purification and analysis, cell based assays, gene editing (CRISPR/Cas9), FACS

Excellence in advanced experimental design, analytical strength, problem solving and interpersonal skills with more than 20 peer reviewed publications including 5 first author papers in Cancer Research, FASEB J, MCB, Biochem J

5 years of leading a deep collaborative and productive team to generate high quality data and manage 6 projects of diverse scope involving cross-functional, multi-site activities and effectively supervised 8 junior scientists

Excellent analytical written, verbal and presentation skills and working knowledge in cGMP/GLP and FDA regulations

PROFESSIONAL EXPERIENCE

Research Scientist, Columbia University, Dept. of Pharmacology, New York 1/2011-present

Protein Kinase C enzymatic activities and regulations in cardiac hypertrophy, heart failure, cancer

Systematically conduct proteomic, biophysical (LC-MS, FRET) and enzyme kinetic studies to identify a novel intra-molecular protein interaction and novel phosphorylation site in ATP-binding loop of PKCδ; work is published in MCB

Explore pre-mRNA alternative splicing events associated with cardiac disease; identified and characterized a novel cardiac specific splicing variant of PKCα during heart failure by NGS and q-PCR

Initiate a project to study functions of ATP-binding motif in PKCδ: apply CRISPR/Cas9 tool to generate PKC δ-S357E knocked-in mouse and discover it protects heart against cardiac ischemia reperfusion damage

Identification of protein kinase C α and δ substrates in the context of signaling pathways in cardiovascular diseases with peptide substrate phosphoylation screening and chemical genetics

Strategically combine quantitative ligand-GPCR binding assay, HTRF screening assays and ELISA to assess GPCR activation for drug discovery projects

Maintain mammalian cell cultures, cardiomyocyte primary culture and establish stable cell lines; design and construct plasmid, adenovirus to express PKCδ and mutant proteins in cardiomyocytes and CHO-K1 cells

Design and execute two phenotypic high throughput screenings with FRET and luciferase based assays to discover leading compound and drug targets to prevent ischemia reperfusion injury

Collaborate with a MIT group to study the regulation of epithelial-to-mesenchymal transition mediated by transcriptional factors and protein kinases interaction and to design new therapeutic strategies

Lead the development of multi-institution collaborations and managed 5 projects, 10 scientists across 5 academic labs including one biotech company, resulted in 5 papers published and submitted.

Interpret, analyze and present data including presentations at two international conferences; write protocols, technical reports, manuscripts, NIH funded grant; mentor and train 8 junior scientist to design, execute and interpret experiments

Visiting Scientist, Kindle Biosciences Inc. 7/2015-12/2015

Collaborated with a team of 3 scientists to develop a new quantitative western blotting, ELISA kit and imaging system to facilitate clinical sample measurement

Postdoctoral Fellow, Immunology, Memorial Sloan-Kettering Cancer Center, New York 8/2008-12/2010

Impact of retinol/fenretinide on mitochondrial oxidative metabolism in cancer and diabetes

Employed biochemical, genetic analysis and animal model to discover antagonistic mechanisms of protein kinase C δ and ε in mitochondrial energy homeostasis and signaling

Elucidated the role of Fenretinide in alleviating diabetic symptoms and in improving glucose tolerance by the activation of PKCδ/p66Shc

Developed and optimized cell based assays to monitor cell survival/death; developed fluorescence polarization based assay to measure enzymatic activity

Constructed vectors for PKCδ, ε and shRNA-PKCδ lentiviral expression to produce virus and established stable MEF lines inducibly expressing mutants of PKCs or ShPKCs

Published 2 first author papers in FASEB J, managed daily laboratory operations and supervised 2 summer students

Postdoctoral fellow, Mount Sinai School of Medicine, Dept. of Microbiology, New York 4/2007-8/2008

Biological functions of RACK1 in breast cancer cell proliferation and drug resistance

Investigated RACK1, CIS and dynein-mediated BimEL degradation and apoptosis resistance in breast cancer

Hela S suspension cell culture scale up to over-express flag tagged anti-apoptotic protein, purify and identify protein complex by affinity purification and proteomic mass spectrometry analysis

Awarded an competitive postdoctoral fellowship from Department of Health at New York State (2007-2008)

Graduate assistant, Mount Sinai School of Medicine, Dept. of Microbiology, New York 8/2001-4/2007

Signaling of RTKs, Vav3 in regulation of prostate cancer cell growth, transformation and metastasis

Independently identified Vav3 as biomarker for prostate metastasis and novel Eph-Vav3-Rac1 signaling for its role in inducing tumorigenesis and metastasis by xenograft model, biochemical and genetic knock-down analysis

Maintained more than 50 cancer cell lines and established stable lines to overexpress or knock-down target genes by ShRNA to dissect signaling and molecular mechanism of cell transformation, tumorigenesis in prostate cancer

Developed and executed cell proliferation/cytotoxicity assays to screen chemical compounds to inhibit cancer growth.

Tested tumor growth inhibition and anoikis upon kinase inhibitor treatments in cancer cell lines with the formats of 2D and 3D matrigel culture

Performed microarray and PCR analysis to study the effect of EGF and TGF-β on gene expression profile of RIE cells

Single chain Fv antibody selection by panning a phage display library on cancer cells overexpressing RTKs

Validation robustness, specificity and precision for the EGFR antibody binding assay by flow cytometry

EDUCATION

Ph.D. in Biochemistry, Mount Sinai School of Medicine of New York University 2007

B.S. in Biochemistry, Hangzhou University 1997

TECHNICAL SKILLS

Molecular cloning, shRNA/shRNA design and construction, mutagenesis, Q-PCR, lentivirus and adenovirus generation, CRISPR; FPLC, column chromatography, SDS-PAGE, capillary & 2D-gel electrophoresis, LC-MS; tissue culture, cell transfection, cell line generation; tumorigenesis assays, xenograft mouse model

Cell based and in vitro assays: in vitro kinase assay, luciferase reporter assay, FISH, radio-ligand binding assay, cell cytotoxicity assay, ELISA, HTRF assay, Luminex assay, FRET, ADCC, migration & invasion assay, colony formation,

Software: Excel, PRISM, SAS, PYMOL, Vector NTI

BUSINESS SKILLS

Project initiation, design and management, team leadership and collaboration, time management, oral communication and presentation, grant and manuscript writing, data analysis, trouble shooting

Contact this candidate